- Home
- / Talis Biomedical
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Talis Biomedical financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$1.7
2024-10-29
Market Capitalization
$3 M
2024-10-29
Revenue
$2.1 M
FY, 2023
CreditSafe Score
?
Score changed on Jun 06, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|
| Revenue | 8.2M | 4.8M | 2.1M |
| Cost of goods sold | 8.4M | 41.0K | |
| Gross profit | (3.6M) | 2.1M | |
| Gross profit margin, % | -74.4% | 98.1% | |
| General and administrative expense | 42.4M | 40.7M | 28.2M |
| Operating expense total | 200.0M | 111.6M | 68.9M |
| EBIT | (191.8M) | (115.1M) | (66.8M) |
| EBIT margin, % | -2341.2% | -2392.7% | -3131.0% |
| Net Income | (192.0M) | (113.0M) | (62.0M) |
| EPS | (8.5) | (4.2) | (34.1) |